<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753658</url>
  </required_header>
  <id_info>
    <org_study_id>B7461036</org_study_id>
    <nct_id>NCT04753658</nct_id>
  </id_info>
  <brief_title>Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib</brief_title>
  <official_title>REAL WORLD DATA COLLECTION AMONG PEDIATRIC NEUROBLASTOMA PATIENTS TREATED WITH LORLATINIB THROUGH EXPANDED ACCESS PROGRAM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The overall goal of this real-world data collection is to assess demographic, clinical&#xD;
      characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with&#xD;
      lorlatinib through the expanded access program.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response of primary tumor (soft tissue), soft tissue metastasis, and bone metastasis</measure>
    <time_frame>March 2017- December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone marrow response</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Health care professional (HCP) Reported Objective Response</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Derived Objective Response</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Best Overall response</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of treatment</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients reporting Adverse Events (AE)</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of patients reporting Adverse Events (AE)</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients reporting treatment related Adverse Events (AE)</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of patients reporting treatment related Adverse Events (AE)</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients reporting Serious Adverse Events (SAE)</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of patients reporting treatment related Serious Adverse Events (SAE)</measure>
    <time_frame>March 2017-December 2023</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Pediatric Neuroblastoma Patients Treated with Lorlatinib</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorlatinib</intervention_name>
    <description>Oral</description>
    <arm_group_label>Pediatric Neuroblastoma Patients Treated with Lorlatinib</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Up to 50 pediatric patients with ALK-aberrant neuroblastoma being treated with lorlatinib&#xD;
        as part of expanded access program will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient receives lorlatinib through Pfizer's expanded access program for treatment of&#xD;
             ALK+ neuroblastoma.&#xD;
&#xD;
          -  HCP documentation of at least one tumor assessment of response after patient has had&#xD;
             at least one dose of lorlatinib&#xD;
&#xD;
          -  Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the patient (or a legally acceptable representative) has been informed of all&#xD;
             pertinent aspects of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient who does not meet any of the inclusion criteria defined in the previous&#xD;
             section.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pennsylvania School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7461036</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

